ClinicalTrials.gg
CompletedNCT00322335Updated Oct 20, 2016Results posted

Long-term Persistence Study to Assess a Booster Dose of GSK Biologicals' Hib-MenC

A Phase 3 interventional study of Haemophilus influenzae type b- and meningococcal (vaccine) and Infanrix™ penta in Haemophilus Influenzae Type b and Neisseria Meningitidis, sponsored by GlaxoSmithKline. Completed at 12 sites in Spain. Open to participants aged 31 Months to 33 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-10-20.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
230
Allocation
Non-randomized
Ages
31 Months to 33 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 82 studies in Haemophilus Infections by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Haemophilus Infections · GlaxoSmithKline.

Enrollment
63rd of 80
230 · median 445
Started
2006
with 13 others
Phase 3
48 of 82
none open now
Registered
26th of 82
by date

Among the 82 studies in Haemophilus Infections by GlaxoSmithKline, this one is the 63rd largest by enrollment of the 80 interventional ones that give a count, is one of 14 that started in 2006, is one of 48 in phase 3, and was the 26th registered.

Haemophilus Infections

176 studies on the registry are indexed under Haemophilus Infections; 5 are open to participants now.

Browse Haemophilus Infections studies →

Open to participants now

None of the 82 studies in Haemophilus Infections by GlaxoSmithKline is open now. The open studies under Haemophilus Infections, anywhere →

Who these studies take

Of the 3 Haemophilus Infections studies recruiting now, none set no upper age limit and 3 stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 31 Months to 33 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 82 studies in Haemophilus Infections by GlaxoSmithKline as a file.
02

Study summary

This protocol posting deals with objectives \& outcome measures of the extension phase at Months 18, 30, 42, 54 and 66 post booster. The objectives \& outcome measures of the primary phase are presented in a separate protocol posting (NCT number = NCT00352963). The objectives \& outcome measures of the Booster phase/study are presented in a separate protocol posting (NCT number =NCT00323050).

The purpose of this study is to evaluate the persistence of meningococcal serogroup C and Hib antibodies on a yearly basis for a period of 5.5 years after booster vaccination. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

Read the detailed description

This multicenter study is open. No vaccine will be administered during this persistence phase of the study. The subjects were randomized in the primary vaccination study 217744/097 (DTPa-HBV-IPV-097) and will not be further randomized in this study. The study has 3 groups with Meningitec™ primed group as control. The protocol was amended to allow for enrollment of subjects of the Meningitec™ primed control group who were boosted with Meningitec™ after the end of the booster study as per new local reccommendation in Spain.

03

Conditions studied

  • Haemophilus Influenzae Type b
  • Neisseria Meningitidis

Keywords

  • H.influenzae type b Disease
04

Who can participate

Ages eligible
31 Months to 33 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol.
  • A male or female in their third year of life at the time of the study initiation for the subjects who enter the study at Visit 1. The subjects who enter the study at Visit 2 should be in their fourth year of life at the time of the study initiation.
  • Written obtained from the parent or guardian of the subject.
  • Healthy subjects as established by medical history and clinical examination before entering into the study.
  • Having completed the booster vaccination study Hib-MenC-TT-010 BST:DTPA--IPV-097 (NCT=00323050).
  • Subjects who are part of the Meningitec™ control group and who were not enrolled at Visit 1 can be enrolled at Visit 2 if they have completed the booster vaccination study Hib-MenC-TT-010 BST:DTPA-HBV-IPV-097 (NCT=00323050) and if they have received a fourth dose of Meningitec™ in their second year of life, after the booster study Hib-MenC-TT-010 BST:DTPA-HBV-IPV-097 (NCT=00323050)

Exclusion criteria

Exclusion Criteria:

  • Previous administration of a booster dose of Hib or meningococcal serogroup C except booster study vaccines during the study Hib-MenC-TT-010 BST:DTPA--IPV-097. Subjects who received a 4th dose of Meningitec™ should be included in the study.
  • History of H. influenzae type b, meningococcal serogroup C diseases.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
230 participants (actual)

Study arms

  • Experimental
    Menitorix/Pediarix Group

    Subjects were primed with 3 doses of Pediarix™ co-administered intramuscularly with Menitorix™ in the right and left thigh respectively in the primary study (NCT00352963) at 2, 4 and 6 months of age. This was followed by a booster dose of Menitorix™ administered intramuscularly in the left thigh between 13 and 14 months of age in study NCT00323050. No vaccines were administered during this long-term persistence phase of the study.

    Biological: Haemophilus influenzae type b- and meningococcal (vaccine) · Biological: Infanrix™ penta

  • Active comparator
    Infanrix hexa (or IPV/Hib)/NeisVac-C/Engerix-B/Menitorix Group

    Subjects were either primed in the primary study (NCT00352963) with 3 doses of Infanrix™ hexa administered intramuscularly in the right thigh at 2, 4 and 6 months of age and 2 doses of NeisVac-C™ administered intramuscularly in the left thigh at 2 and 4 months of age or with Engerix-B at birth intramuscularly in the right thigh, Infanrix™ hexa intramusculary in the right thigh at 2 and 6 months of age and NeisVac-C™ intramuscularly in the left thigh at 2 and 4 months of age, Infanrix™ IPV/Hib was administered intramuscularly in the right thigh at 4 months of age. All subjects were boosted with Menitorix™ administered intramuscularly in the left thigh between 13 and 14 months of age in study NCT00323050. No vaccines were administered during this long-term persistence phase of the study.

    Biological: Haemophilus influenzae type b- and meningococcal (vaccine) · Biological: Infanrix™ hexa · Biological: Engerix-B · Biological: NeisVac-C™ · Biological: Infanrix™ IPV/HIB

  • Active comparator
    Infanrix hexa/Meningitec Group

    Subjects were primed with Infanrix™ hexa co-administered intramuscularly with Meningitec™ in the right and left thigh respectively at 2, 4 and 6 months of age during the primary study (NCT00352963), followed by a booster dose of Infanrix™ hexa intramuscularly in the right thigh between 13 and 14 months of age in study (NCT00323050). No vaccines were administered during this long-term persistence phase of the study.

    Biological: Infanrix™ hexa · Biological: Meningitec™

Interventions

  • BiologicalHaemophilus influenzae type b- and meningococcal (vaccine)

    Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age (group HibMenC) and as booster dose at 14 months of age (groups HibMenC and group NeisPoo).

  • Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age

  • Intramuscular injection into the thigh as primary vaccination at 2, 4 and/or 6 months of age (groups NeisPoo and MenCCRM) and/or as booster dose at 14 months of age (group MenCCRM).

  • BiologicalEngerix-B

    Intramuscular injection into the thigh as a birth dose

  • BiologicalNeisVac-C™

    Intramuscular injection into the thigh as primary vaccination at 2 and 4 months of age.

  • BiologicalInfanrix™ IPV/HIB

    Intramuscular injection into the thigh as primary vaccination at 4 months of age

  • BiologicalMeningitec™

    Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers Equal to or Above Cut-off Value of 1:8

    The cut-off value for the rSBA-MenC titers was equal to or above 1:8. 0 has been put as an arbitrary value for Month 18 in the Infanrix Hexa/Meningitec Group, as it was not addressed for reasons explained in the participant flow section.

    Time frame: 18, 30, 42, 54 and 66 months after booster dose (day 0)

  2. Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers Equal to or Above Cut-off Value of 1:32

    The cut-off value for the rSBA-MenC titers was equal to or above 1:32. 0 has been put as an arbitrary value for Month 18 in the Infanrix Hexa/Meningitec Group, as it was not addressed for reasons explained in the participant flow section.

    Time frame: 18, 30, 42, 54 and 66 months after booster dose (day 0)

  3. Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers Equal to or Above Cut-off Value of 1:128

    The cut-off value for the rSBA-MenC titers was equal to or above 1:128. 0 has been put as an arbitrary value for Month 18 in the Infanrix Hexa/Meningitec Group, as it was not addressed for reasons explained in the participant flow section.

    Time frame: 18, 30, 42, 54 and 66 months after booster dose (day 0)

  4. rSBA-MenC Titers

    Titers are expressed as Geometric Mean Titers (GMTs). 0 has been put as an arbitrary value for Month 18 in the Infanrix Hexa/Meningitec Group, as it was not addressed for reasons explained in the participant flow section.

    Time frame: 18, 30, 42, 54 and 66 months after booster dose (day 0)

  5. Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Concentrations Equal to or Above Cut-off Value of 0.15 µg/mL (Microgram Per Milliliter)

    The cut-off value was an anti-PRP concentration equal to or above 0.15 µg/mL (microgram per milliliter).

    Time frame: 18, 30, 42, 54 and 66 months after the booster dose (day 0)

  6. Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Concentrations Equal to or Above Cut-off Value of 1.0 µg/mL (Microgram Per Milliliter)

    The cut-off value was an anti-PRP concentration equal to or above 1.0 µg/mL (microgram per milliliter).

    Time frame: 18, 30, 42, 54 and 66 months after the booster dose (day 0)

  7. Anti-PRP Concentrations

    Concentrations are expressed as Geometric Mean Concentrations (GMCs) in µg/mL (microgram per milliliter).

    Time frame: 18, 30, 42, 54 and 66 months after the booster dose (day 0)

  8. Number of Subjects With Anti-polysaccharide C (Anti-PSC) Concentrations Equal to or Above Cut-off Value of 0.3 µg/mL (Microgram Per Milliliter)

    The cut-off value was an anti-PSC concentration equal to or above 0.3 µg/mL (microgram per milliliter). 0 has been put as an arbitrary value for Month 18 in the Infanrix Hexa/Meningitec Group, as it was not addressed for reasons explained in the participant flow section.

    Time frame: 18, 30, 42, 54 and 66 months after the booster dose (day 0)

  9. Number of Subjects With Anti-polysaccharide C (Anti-PSC) Concentrations Equal to or Above Cut-off Value of 2.0 µg/mL (Microgram Per Milliliter)

    The cut-off value was an anti-PSC concentration equal to or above 2.0 µg/mL (microgram per milliliter). 0 has been put as an arbitrary value for Month 18 in the Infanrix Hexa/Meningitec Group, as it was not addressed for reasons explained in the participant flow section.

    Time frame: 18, 30, 42, 54 and 66 months after the booster dose (day 0)

  10. Anti-PSC Concentrations

    Concentrations for anti-PSC antibody were expressed as GMCs.

    Time frame: 18, 30, 42, 54 and 66 months after the booster dose (day 0)

  11. Number of Subjects With Serious Adverse Events

    Serious adverse events assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.

    Time frame: From last study contact of the booster study (NCT00323050) to Month 66 after booster dose (day 0)

07

Results

Posted Jan 14, 2011

Participant flow

The follow-up timepoints include all subjects who came back for that timepoint. Therefore the amount of subjects who completed the previous timepoint does not correspond with the amount of subjects starting the following time-point per se.

Subjects 18 Months After Booster Dose
Participant flow — Subjects 18 Months After Booster Dose
MilestoneMenitorix/Pediarix GroupInfanrix Hexa (or IPV/Hib)/NeisVac-C/Engerix-B/Menitorix GroupInfanrix Hexa/Meningitec Group
Started581233
Completed581233
Not completed000
Subjects 30 Months After Booster Dose
Participant flow — Subjects 30 Months After Booster Dose
MilestoneMenitorix/Pediarix GroupInfanrix Hexa (or IPV/Hib)/NeisVac-C/Engerix-B/Menitorix GroupInfanrix Hexa/Meningitec Group
Started5411957
Completed5411957
Not completed000
Subjects 42 Months After Booster Dose
Participant flow — Subjects 42 Months After Booster Dose
MilestoneMenitorix/Pediarix GroupInfanrix Hexa (or IPV/Hib)/NeisVac-C/Engerix-B/Menitorix GroupInfanrix Hexa/Meningitec Group
Started5111356
Completed5111356
Not completed000
Subjects 54 Months After Booster Dose
Participant flow — Subjects 54 Months After Booster Dose
MilestoneMenitorix/Pediarix GroupInfanrix Hexa (or IPV/Hib)/NeisVac-C/Engerix-B/Menitorix GroupInfanrix Hexa/Meningitec Group
Started5010856
Completed5010856
Not completed000
Subjects 66 Months After Booster Dose
Participant flow — Subjects 66 Months After Booster Dose
MilestoneMenitorix/Pediarix GroupInfanrix Hexa (or IPV/Hib)/NeisVac-C/Engerix-B/Menitorix GroupInfanrix Hexa/Meningitec Group
Started4810453
Completed4810453
Not completed000

Outcome measures

PrimaryNumber of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers Equal to or Above Cut-off Value of 1:8

The cut-off value for the rSBA-MenC titers was equal to or above 1:8. 0 has been put as an arbitrary value for Month 18 in the Infanrix Hexa/Meningitec Group, as it was not addressed for reasons explained in the participant flow section.

Time frame:
18, 30, 42, 54 and 66 months after booster dose (day 0)
Reported as:
Number · subjects
Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers Equal to or Above Cut-off Value of 1:8
subjectsMenitorix/Pediarix GroupInfanrix Hexa (or IPV/Hib)/NeisVac-C/Engerix-B/Menitorix GroupInfanrix Hexa/Meningitec Group
Month 18 (N= 45; 96; 0)44930
Month 30 (N= 48; 101; 45)399631
Month 42 (N= 50; 110; 52)3910633
Month 54 (N= 49; 106; 51)3810333
Month 66 (N= 46; 101; 46)389528
PrimaryNumber of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers Equal to or Above Cut-off Value of 1:32

The cut-off value for the rSBA-MenC titers was equal to or above 1:32. 0 has been put as an arbitrary value for Month 18 in the Infanrix Hexa/Meningitec Group, as it was not addressed for reasons explained in the participant flow section.

Time frame:
18, 30, 42, 54 and 66 months after booster dose (day 0)
Reported as:
Number · subjects
Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers Equal to or Above Cut-off Value of 1:32
subjectsMenitorix/Pediarix GroupInfanrix Hexa (or IPV/Hib)/NeisVac-C/Engerix-B/Menitorix GroupInfanrix Hexa/Meningitec Group
Month 18 (N= 45; 96; 0)40930
Month 30 (N= 48; 101; 45)369425
Month 42 (N= 50; 110; 52)3810030
Month 54 (N= 49; 106; 51)3710029
Month 66 (N= 46; 101; 46)378825
PrimaryNumber of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers Equal to or Above Cut-off Value of 1:128

The cut-off value for the rSBA-MenC titers was equal to or above 1:128. 0 has been put as an arbitrary value for Month 18 in the Infanrix Hexa/Meningitec Group, as it was not addressed for reasons explained in the participant flow section.

Time frame:
18, 30, 42, 54 and 66 months after booster dose (day 0)
Reported as:
Number · subjects
Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers Equal to or Above Cut-off Value of 1:128
subjectsMenitorix/Pediarix GroupInfanrix Hexa (or IPV/Hib)/NeisVac-C/Engerix-B/Menitorix GroupInfanrix Hexa/Meningitec Group
Month 18 (N= 45; 96; 0)27820
Month 30 (N= 48; 101; 45)278012
Month 42 (N= 50; 110; 52)308913
Month 54 (N= 49; 106; 51)278615
Month 66 (N= 46; 101; 46)286918
PrimaryrSBA-MenC Titers

Titers are expressed as Geometric Mean Titers (GMTs). 0 has been put as an arbitrary value for Month 18 in the Infanrix Hexa/Meningitec Group, as it was not addressed for reasons explained in the participant flow section.

Time frame:
18, 30, 42, 54 and 66 months after booster dose (day 0)
Reported as:
Geometric mean · titer
rSBA-MenC Titers
titerMenitorix/Pediarix GroupInfanrix Hexa (or IPV/Hib)/NeisVac-C/Engerix-B/Menitorix GroupInfanrix Hexa/Meningitec Group
Month 18 (N= 45; 96; 0)221.5 (137.2 to 357.7)801.1 (570.3 to 1125.3)0 (0 to 0)
Month 30 (N= 48; 101; 45)109.1 (61.9 to 192.3)441.7 (309.4 to 630.6)40.3 (21.9 to 74.1)
Month 42 (N= 50; 110; 52)98.9 (56.7 to 172.5)409.8 (297.7 to 564.2)36.1 (20.4 to 63.8)
Month 54 (N= 49; 106; 51)90.4 (52.8 to 154.8)344.6 (255.9 to 463.9)36.7 (21.1 to 64.0)
Month 66 (N= 46; 101; 46)121.5 (71.0 to 207.9)227.6 (160.2 to 323.3)42.7 (22.3 to 81.8)
PrimaryNumber of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Concentrations Equal to or Above Cut-off Value of 0.15 µg/mL (Microgram Per Milliliter)

The cut-off value was an anti-PRP concentration equal to or above 0.15 µg/mL (microgram per milliliter).

Time frame:
18, 30, 42, 54 and 66 months after the booster dose (day 0)
Reported as:
Number · subjects
Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Concentrations Equal to or Above Cut-off Value of 0.15 µg/mL (Microgram Per Milliliter)
subjectsMenitorix/Pediarix GroupInfanrix Hexa (or IPV/Hib)/NeisVac-C/Engerix-B/Menitorix GroupInfanrix Hexa/Meningitec Group
Month 18 (N= 56; 122; 3)561213
Month 30 (N= 53; 113; 53)5311253
Month 42 (N= 50; 110; 51)5010951
Month 54 (N= 49; 106; 52)4910552
Month 66 (N= 47; 101; 47)4710146
PrimaryNumber of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Concentrations Equal to or Above Cut-off Value of 1.0 µg/mL (Microgram Per Milliliter)

The cut-off value was an anti-PRP concentration equal to or above 1.0 µg/mL (microgram per milliliter).

Time frame:
18, 30, 42, 54 and 66 months after the booster dose (day 0)
Reported as:
Number · subjects
Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Concentrations Equal to or Above Cut-off Value of 1.0 µg/mL (Microgram Per Milliliter)
subjectsMenitorix/Pediarix GroupInfanrix Hexa (or IPV/Hib)/NeisVac-C/Engerix-B/Menitorix GroupInfanrix Hexa/Meningitec Group
Month 18 (N= 56; 122; 3)441123
Month 30 (N= 53; 113; 53)369840
Month 42 (N= 50; 110; 51)339134
Month 54 (N= 49; 106; 52)278635
Month 66 (N= 47; 101; 47)268426
PrimaryAnti-PRP Concentrations

Concentrations are expressed as Geometric Mean Concentrations (GMCs) in µg/mL (microgram per milliliter).

Time frame:
18, 30, 42, 54 and 66 months after the booster dose (day 0)
Reported as:
Geometric mean · µg/mL (microgram per milliliter)
Anti-PRP Concentrations
µg/mL (microgram per milliliter)Menitorix/Pediarix GroupInfanrix Hexa (or IPV/Hib)/NeisVac-C/Engerix-B/Menitorix GroupInfanrix Hexa/Meningitec Group
Month 18 (N= 56; 122; 3)2.921 (2.150 to 3.968)5.450 (4.390 to 6.766)2.547 (0.390 to 16.651)
Month 30 (N= 53; 113; 53)1.914 (1.383 to 2.648)3.524 (2.813 to 4.415)2.224 (1.578 to 3.133)
Month 42 (N= 50; 110; 51)1.735 (1.243 to 2.423)2.986 (2.395 to 3.722)2.005 (1.365 to 2.946)
Month 54 (N= 49; 106; 52)1.552 (1.154 to 2.087)2.688 (2.149 to 3.361)1.799 (1.267 to 2.555)
Month 66 (N= 47; 101; 47)1.602 (1.107 to 2.320)2.625 (2.113 to 3.261)1.763 (1.170 to 2.657)
PrimaryNumber of Subjects With Anti-polysaccharide C (Anti-PSC) Concentrations Equal to or Above Cut-off Value of 0.3 µg/mL (Microgram Per Milliliter)

The cut-off value was an anti-PSC concentration equal to or above 0.3 µg/mL (microgram per milliliter). 0 has been put as an arbitrary value for Month 18 in the Infanrix Hexa/Meningitec Group, as it was not addressed for reasons explained in the participant flow section.

Time frame:
18, 30, 42, 54 and 66 months after the booster dose (day 0)
Reported as:
Number · subjects
Number of Subjects With Anti-polysaccharide C (Anti-PSC) Concentrations Equal to or Above Cut-off Value of 0.3 µg/mL (Microgram Per Milliliter)
subjectsMenitorix/Pediarix GroupInfanrix Hexa (or IPV/Hib)/NeisVac-C/Engerix-B/Menitorix GroupInfanrix Hexa/Meningitec Group
Month 18 (N= 56; 122; 0)381000
Month 30 (N= 52; 108; 53)195819
Month 42 (N= 49; 107; 52)175217
Month 54 (N= 46; 105; 52)145217
Month 66 (45; 99; 45)123411
PrimaryNumber of Subjects With Anti-polysaccharide C (Anti-PSC) Concentrations Equal to or Above Cut-off Value of 2.0 µg/mL (Microgram Per Milliliter)

The cut-off value was an anti-PSC concentration equal to or above 2.0 µg/mL (microgram per milliliter). 0 has been put as an arbitrary value for Month 18 in the Infanrix Hexa/Meningitec Group, as it was not addressed for reasons explained in the participant flow section.

Time frame:
18, 30, 42, 54 and 66 months after the booster dose (day 0)
Reported as:
Number · subjects
Number of Subjects With Anti-polysaccharide C (Anti-PSC) Concentrations Equal to or Above Cut-off Value of 2.0 µg/mL (Microgram Per Milliliter)
subjectsMenitorix/Pediarix GroupInfanrix Hexa (or IPV/Hib)/NeisVac-C/Engerix-B/Menitorix GroupInfanrix Hexa/Meningitec Group
Month 18 (N= 56; 122; 0)1310
Month 30 (N= 52; 108; 53)1183
Month 42 (N= 49; 107; 52)0142
Month 54 (N= 46; 105; 52)1101
Month 66 (N= 45; 99; 45)080
PrimaryAnti-PSC Concentrations

Concentrations for anti-PSC antibody were expressed as GMCs.

Time frame:
18, 30, 42, 54 and 66 months after the booster dose (day 0)
Reported as:
Geometric mean · µg/mL (microgram per milliliter)
Anti-PSC Concentrations
µg/mL (microgram per milliliter)Menitorix/Pediarix GroupInfanrix Hexa (or IPV/Hib)/NeisVac-C/Engerix-B/Menitorix GroupInfanrix Hexa/Meningitec Group
Month 18 (N= 56; 122; 0)0.50 (0.39 to 0.64)1.01 (0.80 to 1.29)0 (0 to 0)
Month 30 (N= 52; 108; 53)0.26 (0.21 to 0.33)0.47 (0.37 to 0.61)0.30 (0.23 to 0.39)
Month 42 (N= 49; 107; 52)0.25 (0.20 to 0.31)0.40 (0.32 to 0.51)0.28 (0.21 to 0.37)
Month 54 (N= 46; 105; 52)0.24 (0.19 to 0.30)0.36 (0.29 to 0.45)0.26 (0.20 to 0.32)
Month 66 (N= 45; 99; 45)0.22 (0.18 to 0.27)0.29 (0.23 to 0.36)0.22 (0.18 to 0.28)
PrimaryNumber of Subjects With Serious Adverse Events

Serious adverse events assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.

Time frame:
From last study contact of the booster study (NCT00323050) to Month 66 after booster dose (day 0)
Reported as:
Number · subjects
Number of Subjects With Serious Adverse Events
subjectsMenitorix/Pediarix GroupInfanrix Hexa (or IPV/Hib)/NeisVac-C/Engerix-B/Menitorix GroupInfanrix Hexa/Meningitec Group
Number of Subjects With Serious Adverse Events000

Adverse events

Collected over From the last contact of the booster study (NCT00323050) until Month 66 after the booster dose (day 0).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Menitorix/Pediarix Group—0/58 (0%)—
Infanrix Hexa (or IPV/Hib)/NeisVac-C/Engerix-B/Menitorix Group—0/123 (0%)—
Infanrix Hexa/Meningitec Group—0/57 (0%)—

Baseline characteristics

Age, Continuous
Age, Continuous(Months)Menitorix/Pediarix GroupInfanrix Hexa (or IPV/Hib)/NeisVac-C/Engerix-B/Menitorix GroupInfanrix Hexa/Meningitec GroupTotal
Mean31.3 ± 0.5431.4 ± 0.6431.5 ± 0.8731.4 ± 0.68
Sex: Female, Male
Sex: Female, Male(Participants)Menitorix/Pediarix GroupInfanrix Hexa (or IPV/Hib)/NeisVac-C/Engerix-B/Menitorix GroupInfanrix Hexa/Meningitec GroupTotal
Female275527109
Male316830129
08

Study locations

12 sites
  • GSK Investigational Site
    Almería, 04009, Spain
  • GSK Investigational Site
    Burgos, 09005, Spain
  • GSK Investigational Site
    Gerona, 17002, Spain
  • GSK Investigational Site
    Getafe/Madrid, 28905, Spain
  • GSK Investigational Site
    Madrid, 28007, Spain
  • GSK Investigational Site
    Madrid, 28041, Spain
  • GSK Investigational Site
    Madrid, 28046, Spain
  • GSK Investigational Site
    Marid, 28040, Spain
  • GSK Investigational Site
    Málaga, 29011, Spain
  • GSK Investigational Site
    Móstoles/Madrid, 28935, Spain
  • GSK Investigational Site
    Valladolid, 47010, Spain
  • GSK Investigational Site
    Vélez-Málaga / Málaga, 29700, Spain
09

References and documents

Publications

  • Tejedor JC, Moro M, Merino JM, Gomez-Campdera JA, Garcia-del-Rio M, Jurado A, Diez-Delgado FJ, Omenaca F, Garcia-Sicilia J, Ruiz-Contreras J, Martin-Ancel A, Roca J, Boceta R, Garcia-Corbeira P, Maechler G, Boutriau D; Spanish 102547 Study Group. Immunogenicity and reactogenicity of a booster dose of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine given to toddlers of 13-14 months of age with antibody persistence up to 31 months of age. Pediatr Infect Dis J. 2008 Jul;27(7):579-88. doi: 10.1097/INF.0b013e31816b4561. PubMed 18536619 ↗
  • Tejedor JC, Merino JM, Moro M, Navarro ML, Espin J, Omenaca F, Garcia-Sicilia J, Moreno-Perez D, Ruiz-Contreras J, Centeno F, Barrio F, Cabanillas L, Muro M, Esporrin C, De Torres MJ, Caubet M, Boutriau D, Miller JM, Mesaros N. Five-year antibody persistence and safety following a booster dose of combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine. Pediatr Infect Dis J. 2012 Oct;31(10):1074-7. doi: 10.1097/INF.0b013e318269433a. PubMed 22828645 ↗
  • Tejedor JC et al. Antibody persistence 54 months after a booster dose of combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus-toxoid (HibMenC-TT) conjugate vaccine. Abstract presented at the 29th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID). The Hague, The Netherlands, 7-11 June 2011.
  • Tejedor JC et al. Antibody persistence 66 months after a booster dose of combined Haemophilus influenzae type B-Neisseria meningitidis serogroup C-tetanus-toxoid (Hib-MenC-TT) conjugate vaccine. Abstract presented at the 30th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID), Thessaloniki, Greece, 8-12 May 2012.

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2006, a primary completion of Jul 2006 and a completion of Sep 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2011, 4 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2006
First posted
May 5, 2006
Start
May 2006
Primary completionActual
Jul 2006
CompletionActual
Sep 2010
Results first posted
Jan 14, 2011
Last update
Oct 20, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 20, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00322335
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
May 5, 2006
Start date
May 2006
Primary completion
Jul 2006
Completion
Sep 2010
Results posted
Jan 14, 2011
Last update
Oct 20, 2016

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pediarix

Start the discussion